Phathom Pharmaceuticals (PHAT) Total Non-Current Liabilities (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Total Non-Current Liabilities data on file, last reported at $638.6 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 2.82% year-over-year to $638.6 million in Q1 2026; TTM through Mar 2026 was $638.6 million, a 2.82% increase from a year earlier, with the FY2025 full-year figure at $693.3 million, up 11.75% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $638.6 million, down from $693.3 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for PHAT reached as high as $693.3 million in Q4 2025 and fell as low as $103.5 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $437.1 million across 5 years, with a median of $495.3 million in 2024.
• Across the five-year window, Total Non-Current Liabilities surged 171.94% in 2022 and climbed 2.82% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $232.1 million in 2022, then surged by 105.45% to $476.9 million in 2023, then soared by 30.09% to $620.4 million in 2024, then gained by 11.75% to $693.3 million in 2025, then retreated by 7.9% to $638.6 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $638.6 million in Q1 2026, $693.3 million in Q4 2025, and $651.3 million in Q3 2025.